CORRECTION



Correction: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/ FOXO1 pathway

Wan Li^{1,2†}, Jie Yi^{3†}, Xiangjin Zheng^{1,2}, Shiwei Liu⁴, Weiqi Fu^{1,2}, Liwen Ren^{1,2}, Li Li², Dave S. B. Hoon⁵, Jinhua Wang^{1,2*} and Guanhua Du^{1,2*}

Correction: Clinical Epigenetics (2018) 10:64 https://doi.org/10.1186/s13148-018-0495-y

In the original publication of this article [1], there was an error in the Fig. 6. The MDA-MB-231 Invasion Cntl group in Fig. 6g and the MDA-MB-436 Migration Cntl group in Fig. 6h were wrongly chosen. The incorrect and correct Fig. 6 are shown in this correction article.

[†]Equal contributors

The original article can be found online at https://doi.org/10.1186/s13148-018-0495-y.

*Correspondence:

Jinhua Wang

wjh@imm.ac.cn Guanhua Du

duah@imm ac

dugh@imm.ac.cn

¹ The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China

² Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China

³ Department of Clinical Laboratory, Peking Union Medical College

Hospital, Beijing 100730, China

⁴ Department of Endocrinology, Shanxi DAYI Hospital, Shanxi Medical University, Taiyuan 030002, Shanxi, China

⁵ Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Incorrect Fig. 6.



(See figure on next page.)

Fig. 6 Knockdown of DNMT3B inhibited the proliferation, migration, and invasion in MDA-MB-231 and MDA-MB-436 cells. **a** Protein levels of DNMT3B detected by Western blotting in MDA-MB-231 cells after the transfection of DNMT3B siRNA 1 and 2. **b** Protein levels of DNMT3B detected by Western blotting in MDA-MB-436 cells after the transfection of DNMT3B siRNA 1 and 2. **c** Quantification of DNMT3B protein levels in MDA-MB-436 cells after the transfection of DNMT3B siRNA 1 and 2. **c** Quantification of DNMT3B protein levels in MDA-MB-436 cells after the transfection of DNMT3B siRNA 1 and 2. **c** Quantification of DNMT3B siRNA 1 and 2. **c** Quantification of DNMT3B protein levels in MDA-MB-436 cells after the transfection of DNMT3B siRNA 1 and 2. **c** Quantification of DNMT3B siRNA 1 and 2. **c** CCK-8 proliferation assays of MDA-MB-231 cells after the transfection of DNMT3B siRNA. **f** CCK-8 proliferation assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. **g** Migration and invasion assays of MDA-MB-231 cells after the transfection of DNMT3B siRNA. **b** Migration and invasion assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. **b** Migration and invasion assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. **b** Migration and invasion assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. **b** Migration and invasion assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. **b** Migration and invasion assays of MDA-MB-436 cells after the transfection of DNMT3B siRNA. Data are presented as mean ± SD from three independent experiments, and every experiment was repeated three times

Correct Fig. 6.



Fig. 6 (See legend on previous page.)

Published online: 27 December 2024

Reference

 Li W, Yi J, Zheng X, et al. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin Epigenet. 2018;10:64.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.